Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,570,770 shares of the company's stock after acquiring an additional 25,704 shares during the period. Vanguard Group Inc. owned about 8.27% of Medpace worth $854,087,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Pallas Capital Advisors LLC boosted its position in Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Barclays PLC raised its stake in shares of Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after buying an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC boosted its position in shares of Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after buying an additional 844 shares in the last quarter. Janus Henderson Group PLC grew its stake in Medpace by 10.0% in the 3rd quarter. Janus Henderson Group PLC now owns 44,118 shares of the company's stock valued at $14,722,000 after acquiring an additional 4,023 shares during the last quarter. Finally, SYM FINANCIAL Corp purchased a new position in Medpace during the 4th quarter valued at about $320,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent research reports. Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, Leerink Partnrs upgraded Medpace to a "hold" rating in a report on Monday, March 24th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $376.30.

Remove Ads

Medpace Stock Performance

NASDAQ MEDP traded down $7.12 during trading hours on Thursday, hitting $304.11. 564,127 shares of the company's stock were exchanged, compared to its average volume of 304,619. The business's 50 day moving average is $332.70 and its 200-day moving average is $338.09. Medpace Holdings, Inc. has a 12-month low of $289.01 and a 12-month high of $459.77. The firm has a market capitalization of $9.27 billion, a P/E ratio of 24.08, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.